Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 8/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 8/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 7/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 7/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 7/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 7/20 | 0.36 |
| ▸ | DRD3 | P35462 | 7/20 | 0.36 |
| ▸ | DRD4 | P21917 | 6/20 | 0.36 |
| ▸ | ADRA1B | P35368 | 5/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.36 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.36 |
| ▸ | DRD1 | P21728 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5425309 | 0.94 | HTR2A (0.37) | DRD2ADRA1BADRA1AADRA1D | |
| SCHEMBL5410015 | 0.88 | ADRA1B (0.43) | DRD2ADRA1BADRA1AADRA1D | |
| SCHEMBL5415645 | 0.88 | DRD2 (0.35) | DRD2DRD3 | |
| SCHEMBL5412606 | 0.87 | ADRA1B (0.40) | DRD2ADRA1BADRA1AADRA1DKCNH2 | |
| SCHEMBL5405065 | 0.85 | DRD2 (0.38) | DRD2DRD3 | |
| SCHEMBL5412551 | 0.85 | NR1H4 (0.39) | DRD2CHRM1CHRM2CHRM4CHRM5 | |
| SCHEMBL5596408 | 0.83 | DRD2 (0.33) | DRD2DRD3ADRA1BADRA1AADRA1D | |
| SCHEMBL5412392 | 0.83 | ADRA1B (0.39) | DRD2CHRM1CHRM2CHRM4CHRM5 | |
| SCHEMBL5410473 | 0.82 | NOS3 (0.42) | DRD2DRD3 | |
| SCHEMBL5413655 | 0.82 | DRD2 (0.36) | DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7160894-B2 | Antagonist of phosphorylation of myosin regulatory light chain, enzyme inhibitors; therapeutic treatment of glaucoma, bronchial asthma, chronic obstructive pulmonary disease, nervous system disorders; 4-(2,3-dihydro-1,5-diazaphenalen-1-yl)cyclohexylamine | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-01-09 | — | — | US | disclosed |
| EP-1632492-A1 | TRICYCLIC COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2006-03-08 | — | — | EP | disclosed |
| US-20050096310-A1 | Tricyclic compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2005-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096310-A1 | Tricyclic compound | MYLK3, CSNK1A1L, MYLK | DRD2 2064/4885CHRM1 15/4885CHRM2 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.